Physician profile
Muhammad Ghumman
NPI 1265670251
$2,080.72
in general payments reported to CMS, 2019-2025
21 companies · $377 in 2025
The $377 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $198 · 2021: $195 · 2022: $331 · 2023: $309 · 2024: $404 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $296.88 | 2021-2023 | Diamondback Coronary |
| Kestra Medical Technology Services, INC. | $256.86 | 2023-2025 | Assure Wcd |
| Medtronic, INC. | $233.52 | 2024-2025 | Symplicity G3 |
| Abiomed | $203.24 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $134.67 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.50 | 2020-2025 | Lifevest |
| Shockwave Medical, INC | $100.00 | 2025 | |
| Boston Scientific Corporation | $96.99 | 2022-2024 | Angiojet Xmi, Rotapro |
| Heartflow, INC. | $94.10 | 2024-2025 | |
| Amgen INC. | $90.84 | 2022-2025 | Repatha, Repatha |
| Acist Medical Systems, INC. | $75.82 | 2020 | |
| Abbott Laboratories | $72.70 | 2022-2025 | Aveir, Diamondback Coronary |
| Medtronic Vascular, INC. | $60.05 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $53.89 | 2022 | |
| Penumbra, INC. | $53.48 | 2023-2024 | Indigo System, Smart Coil |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $48.39 | 2022-2025 | Barostim Neo System |
| Akcea Therapeutics, INC. | $26.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.80 | 2019 | |
| Livanova USA, INC. | $14.98 | 2021 | |
| Celonova Biosciences, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ghumman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.